HK Stock Market Move | LENOVO GROUP (00992) falls over 7%, currently the worst-performing blue chip; Intel warns of another 10% contraction in the PC market next year
LENOVO GROUP (00992) fell over 7%, currently the worst-performing blue chip. As of press time, it was down 6.96% at HK$20.6, with a turnover of HK$2.797 billion.
LENOVO GROUP (00992) fell over 7%, temporarily leading the decline among blue-chip stocks. As of press time, it was down 6.96% at HK$20.6, with a turnover of HK$2.797 billion.
On the news front, Intel's weak business outlook reflects the poor performance of the PC market. Dell Technologies fell nearly 7% after hours, while HP and Hewlett Packard Enterprise fell nearly 6%. The company expects the global PC market to shrink 10% in 2027, after already declining 12% in 2026. In addition, the divergent earnings of US tech giants have further intensified market concerns over the AI investment return cycle.
Orient said in a recent research report that some investors are concerned about the pressure on Lenovo's performance from declining shipments in markets such as PCs. The bank believes the company is expected to offset the impact of falling sales through higher average selling prices, a larger share of high-end products, a better AI PC product mix, and procurement scale.
Related Articles

HK Stock Market Move | Dajin Heavy Industry (01081) falls over 6%; shipment pace and foreign exchange drag down Q3 report; Citi cuts company's net profit forecast.

A-share Market Close | Shanghai Composite Falls 1.44%, Losing 3,600 Points; Liquor and Shipping Stocks Buck the Trend

Sanofi (SNY.US) Q3 profit far exceeds expectations; strong Dupixent demand cannot mask patent cliff concerns.
HK Stock Market Move | Dajin Heavy Industry (01081) falls over 6%; shipment pace and foreign exchange drag down Q3 report; Citi cuts company's net profit forecast.

A-share Market Close | Shanghai Composite Falls 1.44%, Losing 3,600 Points; Liquor and Shipping Stocks Buck the Trend

Sanofi (SNY.US) Q3 profit far exceeds expectations; strong Dupixent demand cannot mask patent cliff concerns.






